Search

Your search keyword '"Hatanaka, Takeshi"' showing total 991 results

Search Constraints

Start Over You searched for: Author "Hatanaka, Takeshi" Remove constraint Author: "Hatanaka, Takeshi"
991 results on '"Hatanaka, Takeshi"'

Search Results

1. Constraint-Driven Multi-USV Coverage Path Generation for Aquatic Environmental Monitoring

2. Angle-Aware Coverage with Camera Rotational Motion Control

3. Net-Zero Energy House-oriented Linear Programming for the Sizing Problem of Photovoltaic Panels and Batteries

4. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

5. Stochastic Optimal Investment Strategy for Net-Zero Energy Houses

6. Convergence Rate Bounds for the Mirror Descent Method: IQCs, Popov Criterion and Bregman Divergence

7. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

8. 3D Map Reconstruction of an Orchard using an Angle-Aware Covering Control Strategy

9. Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices

10. Automatic Generation of Ice Hockey Defensive Motion via Coverage Control and Control Barrier Functions

11. Passivity-based Analysis and Design for Population Dynamics with Conformity Biases

12. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

13. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

15. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

16. Smooth Dynamics for Distributed Constrained Optimization with Heterogeneous Delays

18. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis

19. Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

20. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

21. Instant MPC for linear systems and dissipativity-based stability analysis

22. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

23. Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

24. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

29. Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin–bilirubin score (ALBS grade)

31. Passivity-Based Generalization of Primal-Dual Dynamics for Non-Strictly Convex Cost Functions

35. C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib

37. A Passivity-Based Distributed Reference Governor for Constrained Robotic Networks

38. An Integrated Design of Optimization and Physical Dynamics for Energy Efficient Buildings: A Passivity Approach

39. Stochastic optimal investment strategy for net‐zero energy houses.

40. Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.

41. Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.

48. Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study

49. Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study

Catalog

Books, media, physical & digital resources